The Medicines Company Is Almost Ready To Celebrate Angiomax Patent Term Extension
This article was originally published in The Pink Sheet Daily
Executive SummaryStudies of additional indications for the product may resume as the Patent and Trademark Office assesses the potential length of the extension, which could protect the product until mid-2015.
You may also be interested in...
District Court upholds validity of TMC’s process patents for its anticoagulant but finds Hospira does not infringe them.